Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Efficacy of apatinib on advanced ovarian cancer patients who failed first and second-line chemotherapy

Aiping Wen^1,2, Lei Zhao³, Le Luo⁴, Chengchao Du² Xin Luo¹

¹Department of Gynecology and Obstetrics, The 1st Affiliated Hospital of Jinan University, Guangzhou, China; ²Department of Gynecology and Obstetrics, Affiliated Hospital of North Sichuan Medical College, Nanchong, China; ³Department of Gynecology and Obstetrics, Dujiangyan Medical Center, Chengdu, China; ⁴Sichuan Key Laboratory of Medical Imaging, Affiliated Hospital of North Sichuan Medical College, Nanchong, China.

For correspondence:- Xin Luo Email: doctorapw@163.com Tel:+8613392692068

Accepted: 5 May 2023 Published: 30 May 2023

Citation: Wen A, Zhao L, Luo L, Du C.Luo X. Efficacy of apatinib on advanced ovarian cancer patients who failed first and second-line chemotherapy. Trop J Pharm Res 2023; 22(5):1087-1092 doi: 10.4314/tjpr.v22i5.22

© 2023 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the efficacy and safety of apatinib in the treatment of advanced epithelial ovarian cancer (EOC) patients who failed first and second-line chemotherapy.

Methods: The clinical data of 100 patients diagnosed with advanced ovarian cancer were retrospectively analyzed. They were divided into two groups, with 50 patients in each group. One group was treated with apatinib mesylate (Apatinib group), while the other group was treated with gemcitabine (Gemcitabine group). Clinical efficacy, adverse reactions, and quality-of-life scores were were assessed, while the survival status of patients was recorded during follow-up.

Results: After treatment, the objective response rate (ORR) and disease control rate (DCR) were 24.0 % (12/50) and 70.0 % (35/50) in Apatinib group, and 12.0 % (6/50) and 52.0 % (26/50) in Gemcitabine group. In terms of adverse reactions, the incidence of hand-foot syndrome and hypertension were significantly higher in Apatinib group than in Gemcitabine group, but the incidence of nausea and vomiting, anemia, neutropenia, and thrombocytopenia were significantly lower in Apatinib group than in Gemcitabine group (p < 0.05). Follow-up results revealed the median overall survival (OS) of patients to be 10.1 and 9.0 months, respectively, in Apatinib and Gemcitabine groups. Results of the log-rank test showed that OS in Apatinib group was significantly longer than that of Gemcitabine group.

Conclusion: Apatinib demonstrates clear effectiveness and a superior safety profile than Gemcitabine in the management of patients with advanced ovarian cancer who did not respond effectively to multiple rounds of chemotherapy

Keywords: Apatinib, Gemcitabine, Ovarian cancer, Objective response rate, Disease control rate, Quality of life